IMMUNOMAGNETIC DEPLETION OF MALIGNANT CELLS FROM AUTOLOGOUS BONE MARROW GRAFT: FROM EXPERIMENTAL MODELS TO CLINICAL TRIALS
- 31 March 1989
- journal article
- research article
- Published by Wiley in European Journal of Immunogenetics
- Vol. 16 (2), 125-136
- https://doi.org/10.1111/j.1744-313x.1989.tb00454.x
Abstract
Using experimental models with normal allogeneic bone marrow (BM) contaminated with Burkitt or neuroblastoma cell lines, and a liquid culture assay, we demonstrated that, when used in optimal conditions, the immunomagnetic depletion technique permitted a reproducible elimination of 3–4 log malignant cells. Results were very similar to those obtained with the complement lysis procedure in Burkitt lymphoma. This immunomagnetic procedure was used in 123 cases of autologous bone marrow transplantation (ABMT) in children with neuroblastoma. The analysis of the cases demonstrated, first, that the procedure induced a significant loss of mononuclear cells but was not toxic for BM precursors. Delays to engraftment observed in a few patients were probably due to the combination of pejorative factors, especially the damage caused to the micro‐environment by previous heavy and prolonged chemotherapy or the double ABMT programme. Second, patients presented with profound T‐cell defect with undetectable IL2 secretion up to 1 year post‐graft but they all had normal NK functions from the first month post‐graft, these functions exceeding normal values on the second and third months post‐graft. Finally, in 20 cases, dual‐immunofluorescence staining permitted the demonstration that the autograft contained malignant cells before purging that were eliminated by the immunomagnetic depletion.This publication has 11 references indexed in Scilit:
- Autologous Bone Marrow Transplantation in Pediatric Solid TumorsPediatric Hematology and Oncology, 1990
- A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 casesCancer Treatment Reviews, 1989
- Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?Journal of Clinical Oncology, 1987
- A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.Journal of Clinical Oncology, 1987
- High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age.Journal of Clinical Oncology, 1987
- Use of a liquid cell culture assay to quantify the elimination of Burkitt lymphoma cells from the bone marrowJournal of Immunological Methods, 1987
- Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observationsBritish Journal of Cancer, 1986
- Bone marrow purging procedure in Burkitt lymphoma with monoclonal antibodies and complement: quantification by a liquid cell culture monitoring systemBritish Journal of Haematology, 1986
- REMOVAL OF NEUROBLASTOMA CELLS FROM BONE MARROW WITH MONOCLONAL ANTIBODIES CONJUGATED TO MAGNETIC MICROSPHERESThe Lancet, 1984
- IMMUNOMAGNETIC REMOVAL OF CALLA POSITIVE CELLS FROM HUMAN BONE MARROWThe Lancet, 1983